Last reviewed · How we verify
Radotinib HCl
Radotinib HCl is a BCR-ABL tyrosine kinase inhibitor designed to block the abnormal protein that causes chronic myeloid leukemia (CML).
Radotinib HCl is a BCR-ABL tyrosine kinase inhibitor designed to block the abnormal protein that causes chronic myeloid leukemia (CML). Used for Chronic myeloid leukemia (CML) in chronic phase and accelerated phase.
At a glance
| Generic name | Radotinib HCl |
|---|---|
| Also known as | SUPECT |
| Sponsor | Il-Yang Pharm. Co., Ltd. |
| Drug class | BCR-ABL tyrosine kinase inhibitor |
| Target | BCR-ABL |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the BCR-ABL tyrosine kinase, radotinib HCl prevents the uncontrolled growth of leukemic cells, leading to a reduction in disease progression and improvement in patient outcomes.
Approved indications
- Chronic myeloid leukemia (CML) in chronic phase and accelerated phase
Common side effects
- Neutropenia
- Thrombocytopenia
- Fatigue
Key clinical trials
- Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib (PHASE1)
- Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
- A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs (PHASE3)
- Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radotinib HCl CI brief — competitive landscape report
- Radotinib HCl updates RSS · CI watch RSS
- Il-Yang Pharm. Co., Ltd. portfolio CI